Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
AssigneeCompass Pathfinder Limited
InventorsDerek John Londesbrough, Christopher Brown, Julian Scott Northen, Gillian Moore, David E. Nichols
Life of this patent
Estimating the term…
Abstract
This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.
Claims29
A pharmaceutical blend comprising crystalline psilocybin and at least one pharmaceutically acceptable excipient,
- wherein the pharmaceutical blend has a blend uniformity of greater than about 95%, and
- wherein the crystalline psilocybin is characterized by X-ray powder diffraction (XRPD) peaks at 17.5±0.1 and 19.7±0.1°2θ.
A plurality of tablets, each comprising crystalline psilocybin,
- wherein the plurality of tablets has a psilocybin content uniformity of greater than about 90%, and
- wherein the crystalline psilocybin is characterized by X-ray powder diffraction (XRPD) peaks at 17.5±0.1 and 19.7±0.1°2θ.
A pharmaceutical blend comprising crystalline psilocybin and one or more pharmaceutically acceptable excipients,
- wherein the pharmaceutical blend has an acceptance value of less than about 15, and
- wherein the crystalline psilocybin is characterized by X-ray powder diffraction (XRPD) peaks at 17.5±0.1 and 19.7±0.1°2θ.
Dependencies are inferred from the claim text.